首页> 外文期刊>British Journal of Radiology >Resolution of symptomatic epidural fibrosis following treatment with combined pentoxifylline-tocopherol.
【24h】

Resolution of symptomatic epidural fibrosis following treatment with combined pentoxifylline-tocopherol.

机译:联合己酮可可碱-生育酚治疗后症状性硬膜外纤维化的缓解。

获取原文
获取原文并翻译 | 示例
           

摘要

Epidural fibrosis (EF) is a major cause of failed back surgery syndrome (FBSS), which induces disabling radiculopathy for which no effective medical treatment exists. Our understanding of the fibrosis mechanisms and our clinical and experimental results for the treatment of radiation-induced fibrosis prompted us to postulate that EF might respond to treatment with combined pentoxifylline (PTX)-tocopherol (Vit.E). 6 weeks after lumbar spine surgery, a 28-year-old man presented with recurrent left L5 sciatica without disc herniation on MRI in December 1993. From 1993 to 1997, he had unrelieved back and leg pain, which became increasingly resistant to intensive medical treatment and to a spinal cord stimulator, and confined him to bed as from December 1997. In 1998, a lumbar CT-scan showed an area of left L4-L5 EF measuring 12 mm x 12 mm, without disc herniation. From April 1998, oral PTX (800 mg day(-1)) and Vit.E (1000 IU day(-1)) were administered daily for 3.5 years and well tolerated. Clinical improvement began during the third month of treatment and continued until total regression of clinical symptoms April 2001. Lumbar MRI in November 2001 showed a surface area of residual EF half the size of the initial area. This is the first report to indicate that antifibrotic treatment using combined PTX-Vit.E may be of potential benefit in the treatment of post-operative EF. Additional studies are required to confirm this potential.
机译:硬膜外纤维化(EF)是失败的背部手术综合症(FBSS)的主要原因,该病会导致致残性神经根病,目前尚无有效的治疗方法。我们对纤维化机制的了解以及我们治疗放射线性纤维化的临床和实验结果促使我们推测EF可能会对己酮可可碱(PTX)-生育酚(Vit.E)的联合治疗产生反应。腰椎手术后6周,1993年12月,一名28岁的男子在MRI上表现为左L5坐骨神经痛反复发作而无椎间盘突出。从1993年至1997年,他的背部和腿部疼痛得到缓解,对强化医疗的抵抗力逐渐增强从1997年12月起,将其限制在床上。1998年,腰部CT扫描显示左L4-L5 EF面积为12 mm x 12 mm,无椎间盘突出。从1998年4月开始,口服PTX(800 mg day(-1))和Vit.E(1000 IU day(-1))服用3.5年,耐受性良好。临床改善始于治疗的第三个月,一直持续到2001年4月临床症状完全消退。2001年11月的腰部MRI显示残留EF的表面积为初始区域大小的一半。这是第一份表明使用联合PTX-Vit.E进行抗纤维化治疗可能对术后EF的治疗具有潜在益处的报告。需要进一步的研究以确认这种潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号